136 related articles for article (PubMed ID: 34397846)
1. Prognostic factors for overall survival in patients with clear cell metastatic renal cell carcinoma: Model development and external validation with Memorial Sloan Kettering Cancer Center model and the international metastatic renal cell carcinoma database consortium model.
Shin D; Jeong CW; Song C; Kang M; Seo SI; Kim JK; Lee H; Chung J; Hong SH; Hwang EC; Kwak C; Park JY
Medicine (Baltimore); 2021 Aug; 100(31):e26826. PubMed ID: 34397846
[TBL] [Abstract][Full Text] [Related]
2. Application of the International Metastatic Renal Cell Carcinoma Database Consortium and Memorial Sloan Kettering Cancer Center Risk Models in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multi-Institutional Retrospective Study Using the Korean Metastatic Renal Cell Carcinoma Registry.
Kim JK; Kim SH; Song MK; Joo J; Seo SI; Kwak C; Jeong CW; Song C; Hwang EC; Seo IY; Lee H; Hong SH; Park JY; Chung J
Cancer Res Treat; 2019 Apr; 51(2):758-768. PubMed ID: 30189720
[TBL] [Abstract][Full Text] [Related]
3. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.
Heng DY; Xie W; Regan MM; Harshman LC; Bjarnason GA; Vaishampayan UN; Mackenzie M; Wood L; Donskov F; Tan MH; Rha SY; Agarwal N; Kollmannsberger C; Rini BI; Choueiri TK
Lancet Oncol; 2013 Feb; 14(2):141-8. PubMed ID: 23312463
[TBL] [Abstract][Full Text] [Related]
4. Development of novel ACN (albumin, C-reactive protein and neutrophil-to-lymphocyte ratio) prognostication model for patients with metastatic renal cell carcinoma receiving first-line molecular-targeted therapy.
Tamura K; Ando R; Takahara K; Ito T; Kanao K; Yasui T; Shiroki R; Miyake H
Urol Oncol; 2021 Jan; 39(1):78.e1-78.e8. PubMed ID: 32958444
[TBL] [Abstract][Full Text] [Related]
5. Improvement of prognosis in patients with metastatic renal cell carcinoma and Memorial Sloan-Kettering Cancer Center intermediate risk features by modern strategy including molecular-targeted therapy in clinical practice.
Kamba T; Yamasaki T; Teramukai S; Shibasaki N; Arakaki R; Sakamoto H; Matsui Y; Okubo K; Yoshimura K; Ogawa O
Int J Clin Oncol; 2014; 19(3):505-15. PubMed ID: 23813043
[TBL] [Abstract][Full Text] [Related]
6. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.
Ko JJ; Xie W; Kroeger N; Lee JL; Rini BI; Knox JJ; Bjarnason GA; Srinivas S; Pal SK; Yuasa T; Smoragiewicz M; Donskov F; Kanesvaran R; Wood L; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Choueiri TK; Heng DY
Lancet Oncol; 2015 Mar; 16(3):293-300. PubMed ID: 25681967
[TBL] [Abstract][Full Text] [Related]
7. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
de Velasco G; Culhane AC; Fay AP; Hakimi AA; Voss MH; Tannir NM; Tamboli P; Appleman LJ; Bellmunt J; Kimryn Rathmell W; Albiges L; Hsieh JJ; Heng DY; Signoretti S; Choueiri TK
Oncologist; 2017 Mar; 22(3):286-292. PubMed ID: 28220024
[TBL] [Abstract][Full Text] [Related]
8. External Validation of the MSKCC and IMDC Risk Models in Patients Treated with Targeted Therapy as a First-line and Subsequent Second-line Treatment: A Japanese Multi-institutional Study.
Tanaka N; Mizuno R; Ito K; Shirotake S; Yasumizu Y; Masunaga A; Ito Y; Miyazaki Y; Hagiwara M; Kanao K; Mikami S; Nakagawa K; Momma T; Masuda T; Asano T; Oyama M; Oya M
Eur Urol Focus; 2016 Aug; 2(3):303-309. PubMed ID: 28723377
[TBL] [Abstract][Full Text] [Related]
9. External validation of the albumin, C-reactive protein and lactate dehydrogenase model in patients with metastatic renal cell carcinoma receiving second-line axitinib therapy in a Japanese multi-center cohort.
Tamura K; Osawa T; Takeuchi A; Minami K; Nakai Y; Ueda K; Ozawa M; Uemura M; Sugimoto M; Ohba K; Suzuki T; Anai S; Shindo T; Kusakabe N; Komiyama M; Tanaka K; Yokomizo A; Kohei N; Shinohara N; Miyake H;
Jpn J Clin Oncol; 2021 Apr; 51(5):810-818. PubMed ID: 33479762
[TBL] [Abstract][Full Text] [Related]
10. A new prognostic model for survival in second line for metastatic renal cell carcinoma: development and external validation.
Derosa L; Bayar MA; Albiges L; Le Teuff G; Escudier B
Angiogenesis; 2019 Aug; 22(3):383-395. PubMed ID: 30739258
[TBL] [Abstract][Full Text] [Related]
11. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
12. Is Memorial Sloan-Kettering Cancer Center risk classification appropriate for Japanese patients with metastatic renal cell carcinoma in the cytokine era?
Shinohara N; Abe T; Mochizuki T; Kashiwagi A; Kanagawa K; Maruyama S; Sazawa A; Oba K; Nonomura K
Urol Oncol; 2013 Oct; 31(7):1276-82. PubMed ID: 21956045
[TBL] [Abstract][Full Text] [Related]
13. Baseline Edmonton Symptom Assessment System and survival in metastatic renal cell carcinoma.
Graham J; Gingerich J; Lambert P; Alamri A; Czaykowski P
Curr Oncol; 2018 Aug; 25(4):e319-e323. PubMed ID: 30111978
[TBL] [Abstract][Full Text] [Related]
14. External validation of the systemic immune-inflammation index as a prognostic factor in metastatic renal cell carcinoma and its implementation within the international metastatic renal cell carcinoma database consortium model.
Chrom P; Zolnierek J; Bodnar L; Stec R; Szczylik C
Int J Clin Oncol; 2019 May; 24(5):526-532. PubMed ID: 30604160
[TBL] [Abstract][Full Text] [Related]
15. Impact of Disagreement Between Two Risk Group Models on Prognosis in Patients With Metastatic Renal-Cell Carcinoma.
Okita K; Hatakeyama S; Tanaka T; Ikehata Y; Tanaka T; Fujita N; Ishibashi Y; Yamamoto H; Yoneyama T; Hashimoto Y; Yoshikawa K; Kawaguchi T; Masumori N; Kitamura H; Ohyama C
Clin Genitourin Cancer; 2019 Jun; 17(3):e440-e446. PubMed ID: 30772204
[TBL] [Abstract][Full Text] [Related]
16. Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era.
Naito S; Kato T; Numakura K; Hatakeyama S; Koguchi T; Kandori S; Kawasaki Y; Adachi H; Kato R; Narita S; Yamamoto H; Ogawa S; Kawamura S; Obara W; Ito A; Nishiyama H; Kojima Y; Ohyama C; Habuchi T; Tsuchiya N
Int J Clin Oncol; 2021 Oct; 26(10):1947-1954. PubMed ID: 34191191
[TBL] [Abstract][Full Text] [Related]
17. Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC).
Marchioni M; Kriegmair M; Heck M; Amiel T; Porpiglia F; Ceccucci E; Campi R; Minervini A; Mari A; Van Bruwaene S; Linares E; Hevia V; Musquera M; D'Anna M; Derweesh I; Bradshaw A; Autorino R; Guruli G; Veccia A; Roussel E; Albersen M; Pavan N; Claps F; Antonelli A; Palumbo C; Klatte T; Erdem S; Mir MC;
Eur Urol Oncol; 2021 Apr; 4(2):256-263. PubMed ID: 33384274
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Stratification of the IMDC Intermediate Risk Group After Treatment With First-line Molecular-targeted Therapy for Metastatic Renal Cell Carcinoma.
Takahara K; Ando R; Kanao K; Ito T; Miyake H; Sumitomo M; Yasui T; Shiroki R
Anticancer Res; 2020 Aug; 40(8):4395-4400. PubMed ID: 32727768
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration.
Bamias A; Tzannis K; Beuselinck B; Oudard S; Escudier B; Diosynopoulos D; Papazisis K; Lang H; Wolter P; de Guillebon E; Stravodimos K; Chrisofos M; Fountzilas G; Elaidi RT; Dimopoulos MA; Bamia C
Br J Cancer; 2013 Jul; 109(2):332-41. PubMed ID: 23807171
[TBL] [Abstract][Full Text] [Related]
20. Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.
Savard MF; Wells JC; Graham J; Dudani S; Steinharter JA; McGregor BA; Donskov F; Bjarnason GA; Vaishampayan UN; Hansen AR; Iafolla MAJ; Zanotti G; Huynh L; Chang R; Duh MS; Heng DYC
Oncologist; 2020 May; 25(5):422-430. PubMed ID: 31971318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
